Terms: = Lung cancer AND MUC16, CA125, CA-125 AND Prognosis
89 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract] [Full Text] [Related]
3. Risk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome.
Liang XL; Su YD; Li XB; Fu YB; Ma R; Yang R; Wu HL; Li Y
World J Surg Oncol; 2024 Jan; 22(1):29. PubMed ID: 38267958
[TBL] [Abstract] [Full Text] [Related]
4. Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
Zhou F; Wang M; Wang Z; Li W; Lu X
BMC Cancer; 2024 Jan; 24(1):28. PubMed ID: 38166691
[TBL] [Abstract] [Full Text] [Related]
5. Identification of hypoxia-related gene signatures based on multi-omics analysis in lung adenocarcinoma.
Luo Q; Li X; Meng Z; Rong H; Li Y; Zhao G; Zhu H; Cen L; Liao Q
J Cell Mol Med; 2024 Jan; 28(2):e18032. PubMed ID: 38013642
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive characterization of muc16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract] [Full Text] [Related]
8. Elastic modulus-reflected liver lesion stiffness relates to worse prognosis in pancreatic cancer patients with liver metastasis.
Dong S; Miao X; Zhang K; Zhu X; Gao Y; Chen H
World J Surg Oncol; 2023 Aug; 21(1):262. PubMed ID: 37620975
[TBL] [Abstract] [Full Text] [Related]
9. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Mang A; Zou W; Rolny V; Reck M; Cigoianu D; Schulze K; Holdenrieder S; Socinski MA; Shames DS; Wehnl B; Patil NS
Tumour Biol; 2024; 46(s1):S177-S190. PubMed ID: 37545290
[TBL] [Abstract] [Full Text] [Related]
10. Development and validation of a muc16 mutation-associated immune prognostic model for lung adenocarcinoma.
Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
[TBL] [Abstract] [Full Text] [Related]
11. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
[TBL] [Abstract] [Full Text] [Related]
12. Genetic analysis of familial predisposition in the pathogenesis of malignant pleural mesothelioma.
Akarsu M; Ak G; Dündar E; Metintaş M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7767-7778. PubMed ID: 37027032
[TBL] [Abstract] [Full Text] [Related]
13. A case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding.
Iwadare T; Kimura T; Nagata Y; Suzuki H; Kunimoto H; Kitabatake H; Seki A; Ochi Y; Hara E; Umemura T
Clin J Gastroenterol; 2023 Jun; 16(3):372-376. PubMed ID: 36781827
[TBL] [Abstract] [Full Text] [Related]
14. Combination of serum ACSL4 levels and low-dose 256-slice spiral CT exhibits the potential in the early screening of lung cancer.
Yu W; Wang L; Liu S; Liu Y; Wang S; Sun X
Medicine (Baltimore); 2023 Feb; 102(5):e32733. PubMed ID: 36749237
[TBL] [Abstract] [Full Text] [Related]
15. Increased levels of N6-methyladenosine in peripheral blood RNA: a perspective diagnostic biomarker and therapeutic target for non-small cell lung cancer.
Yin H; Hong H; Yin P; Lu W; Niu S; Chen X; Xia Y; Jiang P; Huang Z
Clin Chem Lab Med; 2023 Feb; 61(3):473-484. PubMed ID: 36542027
[TBL] [Abstract] [Full Text] [Related]
16. The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell lung cancer and Its Relationship with prognosis.
Zhao Y; He J; Zhou S; Ning R; Zhao W; Wang H; Su C; Jiang W; Zhong X; Yu Q
Comput Math Methods Med; 2022; 2022():1679191. PubMed ID: 36118825
[TBL] [Abstract] [Full Text] [Related]
17. Development of exploratory algorithms to aid in risk of malignancy prediction of indeterminate pulmonary nodules.
Jeanblanc N; Jackson L; Gawel S; Brophy S; Vaidya S; Syed S; Davis GJ; Borgia JA
Clin Chim Acta; 2022 Oct; 535():197-202. PubMed ID: 36087784
[TBL] [Abstract] [Full Text] [Related]
18. Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer.
Li Y; Wang Y; Zhou W; Chen Y; Lou Y; Qian F; Lu J; Jiang H; Xiang B; Zhang Y; Han B; Zhang W
Thorac Cancer; 2022 Oct; 13(19):2711-2722. PubMed ID: 36054506
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic Evaluation of CT Imaging Big Data-Assisted Arterial Chemoembolization Combined with
Xie P; Zhang Y; He L
Comput Math Methods Med; 2022; 2022():3472982. PubMed ID: 35872936
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with lung cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
Wang L; Lei X; Wang X
Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
[TBL] [Abstract] [Full Text] [Related]
[Next]
